# Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

> **NCT07457528** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Resectable Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** HLX10
- **DRUG:** Chemotherapy
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT07457528
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457528, "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07457528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*